Diabetic patients treated with abciximab and intracoronary stenting

Diabetic patients are at greater risk for restenosis, recurrent ischemia, and complications following angioplasty than are their nondiabetic counterparts. This is a retrospective study identifying diabetic patients who were treated with abciximab and intracoronary stenting during the period of Janua...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2002-03, Vol.55 (3), p.321-325
Main Authors: Walton, Brian L., Mumm, Kim, Taniuchi, Megumi, Kurz, Howard I., Lasala, John M.
Format: Article
Language:English
Subjects:
abciximab
Angioplasty, Balloon, Coronary - adverse effects
Antibodies, Monoclonal - administration & dosage
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Combined Modality Therapy
Coronary Restenosis - etiology
Coronary Restenosis - therapy
Diabetes Complications
diabetic
Female
Follow-Up Studies
Humans
Immunoglobulin Fab Fragments - administration & dosage
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Retrospective Studies
Risk
stent
Stents
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic patients are at greater risk for restenosis, recurrent ischemia, and complications following angioplasty than are their nondiabetic counterparts. This is a retrospective study identifying diabetic patients who were treated with abciximab and intracoronary stenting during the period of January 1997 to December 1999. Abciximab was administered to 268 of 707 diabetic patients who received intracoronary stents from 1997 to 1999. The abciximab group contained a higher number of patients with severe ventricular dysfunction and high‐grade lesions. Primary endpoints of all‐cause mortality, same‐vessel revascularization, CABG, TVR, and postprocedural myocardial infarction were similar for both groups. The abciximab group had reduced rates of readmission for cardiac reasons during all follow‐up periods. The trends toward improvement of mortality, surgical or percutaneous revascularization, and cardiac readmissions suggest the effect of abciximab may provide benefit for up to 9 months for higher‐risk diabetic patients. Cathet Cardiovasc Intervent 2002;55:321–325. © 2002 Wiley‐Liss, Inc.
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.10025